

## **NeurAxis to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024**

CARMEL, Ind., May 21, 2024 — NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will participate in a webcasted presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2024 Investor Conference, taking place virtually on Thursday, May 30, 2024.

### **Company Webcast**

The webcasted presentation will take place at 9:30 a.m. ET on Thursday, May 30, 2024. The webcast can be accessed by visiting the conference home page at <https://lythampartners.com/spring2024/> or directly at <https://wsn.com/webcast/lytham11/nrxs/2139291>. The webcast will also be available for replay following the event.

### **1×1 Meetings**

Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at [1x1@lythampartners.com](mailto:1x1@lythampartners.com) or register for the event at <https://lythampartners.com/spring2024invreg/>.

### **About NeurAxis, Inc.**

NeurAxis, Inc., is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis is dedicated to advancing science and leveraging evidence-based medicine to drive adoption of its IB-Stim™ therapy, which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim™ is FDA cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 11-18 years old. Additional clinical trials of PENFS in multiple pediatric and adult conditions with large unmet healthcare needs are underway. For more information, please visit <http://neuraxis.com>.

### **Contacts**

#### **Company**

#### **NeurAxis, Inc.**

[info@neuraxis.com](mailto:info@neuraxis.com)

**Investor Relations**

Lytham Partners

Ben Shamsian

646-829-9701

[shamsian@lythampartners.com](mailto:shamsian@lythampartners.com)

